was read the article
array:22 [ "pii" => "S0365059623000211" "issn" => "03650596" "doi" => "10.1016/j.abd.2022.09.003" "estado" => "S300" "fechaPublicacion" => "2023-05-01" "aid" => "718" "copyright" => "Sociedade Brasileira de Dermatologia" "copyrightAnyo" => "2023" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "pt" => array:18 [ "pii" => "S2666275223000450" "issn" => "26662752" "doi" => "10.1016/j.abdp.2023.02.017" "estado" => "S300" "fechaPublicacion" => "2023-05-01" "aid" => "718" "copyright" => "Sociedade Brasileira de Dermatologia" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "pt" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Educação médica continuada</span>" "titulo" => "Carcinoma de células de Merkel: epidemiologia, características clínicas, diagnóstico e tratamento de doença rara" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "tieneResumen" => "pt" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "277" "paginaFinal" => "286" ] ] "contieneResumen" => array:1 [ "pt" => true ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1889 "Ancho" => 2508 "Tamanyo" => 294872 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Carcinoma de células de Merkel localizado na coxa esquerda de paciente do sexo masculino. (A) Ao diagnóstico, lesão tumoral com aspecto cupuliforme, com eritema e discreta descamação. (B) Evolução do tumor com crescimento e ulceração em toda a lesão.</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Fonte: Cortesia da Dra. Gabriella Campos‐do‐Carmo. O paciente consentiu com o uso das imagens para fins educacionais.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Stella Meireles Siqueira, Gabriella Campos‐do‐Carmo, Alexssandra Lima Siqueira dos Santos, Cícero Martins, Andreia Cristina de Melo" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Stella Meireles" "apellidos" => "Siqueira" ] 1 => array:2 [ "nombre" => "Gabriella" "apellidos" => "Campos‐do‐Carmo" ] 2 => array:2 [ "nombre" => "Alexssandra Lima Siqueira dos" "apellidos" => "Santos" ] 3 => array:2 [ "nombre" => "Cícero" "apellidos" => "Martins" ] 4 => array:2 [ "nombre" => "Andreia Cristina de" "apellidos" => "Melo" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0365059623000211" "doi" => "10.1016/j.abd.2022.09.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059623000211?idApp=UINPBA00008Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275223000450?idApp=UINPBA00008Z" "url" => "/26662752/0000009800000003/v3_202305121556/S2666275223000450/v3_202305121556/pt/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S0365059623000107" "issn" => "03650596" "doi" => "10.1016/j.abd.2022.04.011" "estado" => "S300" "fechaPublicacion" => "2023-05-01" "aid" => "709" "copyright" => "Sociedade Brasileira de Dermatologia" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "A retrospective analysis of Stewart-Treves syndrome in the context of chronic lymphedema" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "287" "paginaFinal" => "295" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 3313 "Ancho" => 3341 "Tamanyo" => 460751 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0055" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">MRI showed nodules distributed on the surface of the skin, subcutaneous tissue and some muscles; it appeared slightly long T1 and short T2 signals. (A) AX fs T2 FSE. (B) AX fs T2 FSE. (C) AXI SE T1. (D) AX T2 FSE.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Kun Hao, Yuguang Sun, Yan Zhu, Jianfeng Xin, Li Zhang, Bin Li, Wenbin Shen" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Kun" "apellidos" => "Hao" ] 1 => array:2 [ "nombre" => "Yuguang" "apellidos" => "Sun" ] 2 => array:2 [ "nombre" => "Yan" "apellidos" => "Zhu" ] 3 => array:2 [ "nombre" => "Jianfeng" "apellidos" => "Xin" ] 4 => array:2 [ "nombre" => "Li" "apellidos" => "Zhang" ] 5 => array:2 [ "nombre" => "Bin" "apellidos" => "Li" ] 6 => array:2 [ "nombre" => "Wenbin" "apellidos" => "Shen" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S2666275223000358" "doi" => "10.1016/j.abdp.2023.02.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275223000358?idApp=UINPBA00008Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059623000107?idApp=UINPBA00008Z" "url" => "/03650596/0000009800000003/v3_202305121633/S0365059623000107/v3_202305121633/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Continuing Medical Education</span>" "titulo" => "Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "277" "paginaFinal" => "286" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Stella Oliveira Meireles Siqueira, Gabriella Campos-do-Carmo, Alexssandra Lima Siqueira dos Santos, Cícero Martins, Andreia Cristina de Melo" "autores" => array:5 [ 0 => array:4 [ "nombre" => "Stella Oliveira Meireles" "apellidos" => "Siqueira" "email" => array:1 [ 0 => "stellamsiqueira@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Gabriella" "apellidos" => "Campos-do-Carmo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Alexssandra Lima Siqueira" "apellidos" => "dos Santos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Cícero" "apellidos" => "Martins" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 4 => array:3 [ "nombre" => "Andreia Cristina" "apellidos" => "de Melo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Division of Clinical Research and Technological Development, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Gávea Medical Center, Rio de Janeiro, RJ, Brazil" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Section of Clinical Oncology, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1889 "Ancho" => 2508 "Tamanyo" => 294872 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Merkel cell carcinoma located on the left thigh of a male patient. (A) At diagnosis, tumor lesion with cupuliform appearance, with erythema and mild desquamation. (B) Tumor evolution with growth and ulceration throughout the lesion. Source: Courtesy of Dr. Gabriella Campos-do-Carmo (the patient consented to the use of images for educational purposes).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Merkel Cell Carcinoma (MCC) is an unusual and aggressive type of skin cancer with neuroendocrine origin,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> and was first described in 1972 by Toker as a trabecular skin carcinoma.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Since then, understanding of its pathophysiology, outcomes and management have improved, especially after immunotherapies. Also known as primary cutaneous neuroendocrine carcinoma, MCC shares features with Merkel cells of the skin, justifying its nomenclature.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Epidemiology</span><p id="par0010" class="elsevierStylePara elsevierViewall">The incidence rate of MCC varies in different regions of the world. In the European Union, between 1995 and 2002, its annual incidence rate was 0.13 per 100,000 inhabitants, but higher in groups aged 65 years or older.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> In the United States, the incidence rate was 0.79 per 100,000 inhabitants in 2011.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> In 2013, Paulson et al. reported that the absolute number of MCC in the United States was 2488 cases, which corresponds to an incidence rate similar to 0.7 per 100,000 person-years.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">A higher incidence of MCC was observed in an Australian study, with a rate of 1.6 per 100,000 inhabitants in the state of Queensland between 2006 and 2010, more frequent in males (2.5 per 100,000) than in females (0.9 per 100,000) and with an average life expectancy of 75.5 years for men and 78 years for women at the diagnosis.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Although rare, the incidence of MCC has increased dramatically.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> In 2018, Paulson et al. reported that the number of cases increased 95% between 2000 and 2013 in the US, compared with an increase of 57% for melanoma and 15% for all other solid tumors.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> In Australia, the overall incidence of MCC increased on average by 2.6% per year between 1993 and 2010 (95% CI: 1.1%‒4.2%).<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> MCC is often underdiagnosed and part of its increased incidence is thought to be due to better-trained pathologists and also to the development of biomarkers that have improved disease detection.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Regarding the epidemiology of MCC in Brazil, Melo et al. published a study with data collected from Population-Based (2000–2015) and Hospital-Based (2000–2017) Cancer Registries. A total of 881 patients with the disease were analyzed, most of which were female (51.2%), aged over 60 years (82.2%), white (67.6%), and diagnosed predominantly in stages III or IV (50.5%). Moreover, age-standardized mean incidence rates were found to increase significantly in men between the years 2000 (0.31/1,000,000) and 2015 (1.21/1,000,000), with an annual percentage variation of 9.4 (95% CI: 4.7–14.4; p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001). Meanwhile, in women, incidence rates did not increase significantly over the period.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Carneiro et al. retrospectively evaluated 32 patients treated at the National Cancer Institute with MCC between 2002 and 2012, and the mean age at diagnosis was 72 years. However, unlike the international data, most patients were female (69%).<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Risk factors</span><p id="par0035" class="elsevierStylePara elsevierViewall">Several studies suggest that multiple factors may contribute to the development of MCC.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,8,11–13</span></a> Sun exposure is an important risk factor,<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13,14</span></a> supported by the higher incidence of MCC in regions with higher rates of ultraviolet radiation,<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,8</span></a> and the greater tendency to occur in sun-exposed areas, such as the head and neck region.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> Lunder et al. also showed a higher occurrence of MCC in patients with a history of psoralen use and skin exposure to longwave ultraviolet radiation.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> MCC is also more frequent in Caucasian patients compared to other ethnicities.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Immunosuppression is also a risk factor,<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> therefore, MCC is more common in transplant recipients, patients diagnosed with lymphoproliferative malignancies (such as chronic lymphocytic leukemia), or patients with HIV.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,14</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">In addition, advanced age is also considered a risk factor.<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13,15</span></a> In a US series, 90% of all patients with MCC were aged over 50 years, 76% were over 65 years, and 49% were over 75 years.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,15</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">In 2008, Feng et al. first described the association between a novel polyomavirus and MCC, identifying viral DNA in 8 of 10 Merkel tumors, suggesting that viral infection could be an early event in the pathogenesis.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Polyomavirus associated with Merkel cell carcinoma</span><p id="par0055" class="elsevierStylePara elsevierViewall">The discovery of the MCC-associated polyomavirus in 2008 revolutionized the knowledge about tumor pathogenesis, and it was named Merkel cell polyomavirus (MCPyV).<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> The association was identified using a digital transcriptome subtraction technique, which is a bioinformatics method used to detect the presence of novel pathogen transcripts through the computational removal of host sequences; therefore, in this case, known human sequences were filtered to identify potential viral transcripts.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">Cases of subclinical MCPyV infection increase with senescence, reaching a prevalence of 60% to 80% in adults. However, this may differ significantly in other geographic regions, such as Australia, where a much lower association with viral infection has been reported, of around 25%.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> The skin constitutes the major viral infection site, although the virus has also been detected in peripheral blood and other organs. MCPyV infection seems to be asymptomatic.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">The <span class="elsevierStyleItalic">Polyomaviridae</span> family, to which MCPyV belongs, consists of small double-stranded DNA viruses. It includes other polyomaviruses associated with cutaneous infection in humans (<span class="elsevierStyleItalic">Trichodysplasia spinulosa</span> polyomavirus, human polyomavirus 6, and human polyomavirus 7) or disease in other organs and systems (such as JC virus, a ubiquitous human polyomavirus that causes central nervous system disease in immunocompromised patients, including progressive multifocal leukoencephalopathy, granular cell neuropathy, and JC virus encephalopathy). To date, MCPyV is the only human oncovirus in the <span class="elsevierStyleItalic">Polyomaviridae</span> family, but the reason for this distinct status is not yet known.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">The specific type of host cell for infection by this polyomavirus remains unclear. Merkel cells are thought to be insufficiently numerous to explain the viral load that is normally detected in the skin, and monocytes in peripheral blood have been implicated as possible reservoirs of infected cells.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">The episomal viral genome has both early and late regions. The former have genes that encode proteins responsible for coordinating viral replication, whereas the latter regions are linked to viral capsid proteins. It seems that the integration of MCPyV DNA into the host genome occurs shortly after the infection.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,18</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">Immunohistochemistry, PCR, <span class="elsevierStyleItalic">in situ</span> DNA hybridization, or next-generation sequencing technologies are available methods to detect MCPyV in tumors, but these tests vary greatly in sensitivity and specificity. The development of a monoclonal antibody used for the specific detection of the large T (LT) antigen through immunohistochemistry ‒ exclusive for MCPyV (the CM2B4 clone) ‒ allowed the detection and observation of MCPyV <span class="elsevierStyleItalic">in situ</span>. This method is commercially available and has approximately 88% sensitivity and 94% specificity.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a><a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a> shows examples of positive and negative immunohistochemistry results for Merkel cell polyomavirus performed using the anti-MCPyV large T-antigen (CM2B4) antibody.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Clinical features</span><p id="par0085" class="elsevierStylePara elsevierViewall">Clinically, MCC can present as a cutaneous or subcutaneous nodule, and even have a cystic appearance. The color can vary between red, pink, blue, violet, or skin color. Initially, the lesions are usually painless and solitary, but they may also ulcerate or be surrounded by satellite lesions. At diagnosis, the dimensions can vary in size but are usually smaller than 20<span class="elsevierStyleHsp" style=""></span>mm, and most cases show rapid tumor growth in a few months<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>).</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0090" class="elsevierStylePara elsevierViewall">The lesions usually appear on photoexposed areas, while 19% appear on the buttocks or areas minimally exposed to the sun. The most frequent primary anatomic sites are the head and neck (29%), followed by the lower limbs (24%) and the upper limbs (21%).<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">Heath et al., in 2008, proposed the mnemonic rule “AEIOU” (Asymptomatic/lack of tenderness, Expanding rapidly, Immune suppression, Older than 50 years and Ultraviolet exposed site) based on the analysis of 195 cases, in an attempt to aid the diagnosis. In this cohort, 89% of the patients diagnosed with MCC met three or more criteria, 52% of the patients met four or more criteria, and 7% of the patients met all five criteria.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">At the time of diagnosis, up to 37% of the patients present with nodal disease and 6%–12% present with metastatic disease.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> About 15% of the patients have a affected lymph node without an identifiable skin lesion, probably reflecting regression of the primary site.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,15</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Distant metastases appear most often in non-regional lymph nodes, skin, bones, lungs and pleura or liver and, less commonly, in the pancreas, adrenal glands, brain, kidneys, subcutaneous tissue or muscle. Rare sites of metastases include breasts, the gastrointestinal tract, testes, heart, retroperitoneum, and the peritoneum.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Diagnosis</span><p id="par0110" class="elsevierStylePara elsevierViewall">Due to the lack of specific features and symptoms, the diagnosis becomes a challenge. Therefore, the histopathological examination by an experienced pathologist and the staining with specific immunohistochemical markers are essential in this process.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">The North American organization National Comprehensive Cancer Network (NCCN) has proposed specific algorithms for the diagnosis of MCC, which include the following strategies: 1) A complete examination of the skin and lymph nodes; 2) Biopsy for histopathological and immunohistochemical analysis; 3) Sentinel lymph node biopsy (SLNB) for patients without clinically positive lymph nodes, preceding the excision, if possible; 4) Fine needle aspiration or lymph node biopsy for patients with clinically positive lymph nodes; consider open biopsy; 5) Imaging exams for staging as clinically indicated.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall">Dermoscopy is a complementary exam that can be useful in some cases, but there is still a lack of more complete dermoscopic descriptions in the literature. MCC often exhibits a variety of dermoscopic vascular patterns, most commonly milky red areas/ globules, polymorphic vessels, and irregular linear vessels,<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> reflecting rapid tumor growth.</p><p id="par0125" class="elsevierStylePara elsevierViewall">Hematoxylin-eosin staining reveals the proliferation of small basophilic tumor cells in the dermis and/or hypodermis,<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> with sparse cytoplasm, abundant mitoses, and dense cytoplasmic granules. Necrotic cells are also common.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,20</span></a> Histopathology examples are depicted in <a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>.</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0130" class="elsevierStylePara elsevierViewall">Cytokeratin 20 (CK20) and neuroendocrine markers such as chromogranin A, synaptophysin, CD56, neuron-specific enolase, and neurofilaments are expressed in MCC.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,14,21</span></a> Paranuclear dot-like immunopositivity for CK20 is highly suggestive, whereas the neuroendocrine markers are non-specific.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">For patients with clinically negative nodes, SLND should be performed and its positivity rate ranges from 30% to 38%.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> When negative, a lower risk of recurrence,<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> better disease free survival (DFS) and overall survival (OS) are observed.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">The use of imaging exams for the diagnostic investigation of patients with MCC is still under discussion. The NCCN does not recommend imaging exams in patients without clinical suspicion of affected lymph nodes. SLND is considered the most reliable test to identify metastases in non-clinically suspicious lymph nodes. Brain magnetic resonance imaging (MRI), neck, chest, abdomen, and pelvis computed tomography scans or PET-CT are indicated for surgical planning or when unresectable tumors or distant metastases are suspected.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">Gupta et al. have shown that computed tomography has low sensitivity, around 20%, for detecting lymph node metastases and low specificity for distant metastases.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> Therefore, although computed tomography has been used as a screening tool for regional or distant metastases in MCC, data supporting its application are limited.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14,22</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">PET-CT has been extensively assessed in patients with MCC.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> Colgan et al. retrospectively evaluated 36 patients with MCC who underwent PET-CT scans prior to SLNB and observed 83% and 95% of sensitivity and specificity, respectively.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Differential diagnosis</span><p id="par0155" class="elsevierStylePara elsevierViewall">Clinically, the differential diagnoses for MCC are benign skin lesions, such as acneiform cyst, lipoma, dermatofibroma or fibroma, and vascular lesions. Malignant lesions represented by non-melanoma skin cancer, cutaneous lymphoma, metastatic carcinoma, and sarcoma should also be considered differential diagnoses.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">Histopathologically, the diagnosis can also be challenging, as MCC is similar to a variety of other tumors that have small, rounded blue cells, including lymphomas, amelanotic melanoma, cutaneous metastases from small cell lung carcinoma,<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> and other metastatic carcinomas (neuroblastoma, rhabdomyosarcoma, desmoplastic small cell tumors, mesenchymal chondrosarcoma, Ewing's sarcoma, and osteosarcoma).<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> MCC <span class="elsevierStyleItalic">in situ</span>, in which neoplastic cells are limited to the epidermis and/or follicular epithelium, may be mistaken for squamous cell carcinoma <span class="elsevierStyleItalic">in situ</span>, melanoma <span class="elsevierStyleItalic">in situ</span>, or other pagetoid intraepidermal neoplasia.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">Due to similar morphological features, the most challenging differential diagnosis is metastatic small-cell lung cancer,<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,8</span></a> which requires a panel of immunohistochemical markers to define the diagnosis. CK20 and thyroid transcription factor 1 (TTF-1) have increased sensitivity and specificity for excluding small cell lung cancer,<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> with CK20 being positive in 70%–100% of MCC cases and negative in small cell lung cancer, whereas TTF-1 is always negative in MCC and positive in more than 80% of small cell lung cancer cases.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,8,14</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Staging</span><p id="par0170" class="elsevierStylePara elsevierViewall">The current 8<span class="elsevierStyleSup">th</span> edition of the American Joint Committee on Cancer (AJCC) staging system is based on an updated analysis of 9387 cases of MCC from the National Cancer Database, with a median follow-up of 28.2 months (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> According to the AJCC, the following parameters are required for the staging of MCC: 1) Maximum clinically measured tumor diameter, prior to resection, and 2) tumor extent (fascia, muscle, cartilage, or bone invasion).<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> Tumor diameter has prognostic value, being significantly associated with lymph node involvement, disease-specific survival (DSS), and OS.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0175" class="elsevierStylePara elsevierViewall">MCC is characteristically an aggressive, locally invasive tumor, with a high incidence of local recurrence and regional lymph node involvement.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> The SLNB is an important staging tool recommended for all patients with a clinically negative node, to perform pathological node staging whenever possible.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">According to the 8th edition of the AJCC staging system, the five-year OS estimates for the clinical and pathological staging of local disease were 45.0% and 62.8% for stage I; 30.9% and 54.6% for stage IIA and 27.3% and 34.8% for stage IIB, respectively. The five-year OS for revised stage IIIA was 40.3%, while it was 26.8%.for stage IIIB.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> In stage IV disease, the two-year survival rate is only 26%.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0185" class="elsevierStylePara elsevierViewall">Sihto et al., in 2009, reported that polyomavirus-positive MCC had a higher survival rate when compared to polyomavirus-negative tumors, with a five-year survival rate of 45% <span class="elsevierStyleItalic">vs</span>. 13% (p-value < 0.01), respectively.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Treatment</span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Surgery for the primary tumor</span><p id="par0190" class="elsevierStylePara elsevierViewall">Surgery is the initial treatment modality for most cases of MCC. The definition of surgical margins is still a controversial topic.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> The goal of surgical treatment is a negative histological margin, and in general, surgical excision with margins of 1–2<span class="elsevierStyleHsp" style=""></span>cm remains the first step in tumor management.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> Boyer et al. analyzed 45 patients with stage I MCC and reported a median margin of 16.7<span class="elsevierStyleHsp" style=""></span>mm of clinically normal skin, necessary for the absence of histopathological involvement.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a></p><p id="par0195" class="elsevierStylePara elsevierViewall">A study of 1795 patients with stage I and II MCC showed no differences between wide surgical excision and Mohs micrographic surgery regarding the presence of residual tumor at the surgical margins, and no difference was observed in OS between the two treatment modalities.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> Histopathologically negative margins are related to better local control and survival, especially in cases of localized disease treated solely with surgery. In all cases of surgical treatment, SLNB should be planned before a definitive excision, as the surgery may alter lymphatic drainage.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">Santamaria-Barria et al. elucidated the role of SLNB in the management of MCC in a review of 161 patients, identifying micrometastases in one-third of them.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> Thus, after checking for free margins and, if indicated, SLNB, the challenge is to determine whether or not to offer adjuvant treatment.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Radiotherapy</span><p id="par0205" class="elsevierStylePara elsevierViewall">Radiotherapy (RT) plays an important role in the treatment of MCC. MCC is a radiosensitive neoplasm and RT may be considered as primary therapy in patients who are not candidates for surgery.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">29,30</span></a> Although RT alone is inferior to surgical resection because of the risk of distant MCC recurrence, it can be used when surgery is contraindicated,<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">31–33</span></a> with good locoregional control and five-year OS of up to 40%–60% in patients with primary macroscopic and/or nodal metastases.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall">Data are conflicting regarding its use as adjuvant therapy. Postoperative adjuvant RT seems to increase local tumor control but has no significant impact on tumor-related overall survival.<a class="elsevierStyleCrossRefs" href="#bib0170"><span class="elsevierStyleSup">34,35</span></a> In a review of head and neck MCC cases only, adjuvant RT showed significant benefit in survival over surgery alone, and chemotherapy (CT) plus RT offered an advantage over RT alone in cases of large tumors (>3<span class="elsevierStyleHsp" style=""></span>cm) or positive margins.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">36</span></a> A retrospective analysis of stage I to III MCC showed a low recurrence rate (3%) in patients with clinically-negative nodes treated with appropriate surgery (including SLNB) and the selective use of adjuvant RT for high-risk tumors, including lymphovascular invasion; second malignancy (leukemia/lymphoma) at diagnosis, multiple positive lymph nodes, and extracapsular extension; tumors >2<span class="elsevierStyleHsp" style=""></span>cm. The authors also conclude that, with adequate surgery, the routine use of adjunctive local RT is unlikely to be beneficial for the vast majority of patients.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> Moreover, some data have suggested that adjuvant RT may be omitted for those with small primary tumors (<1<span class="elsevierStyleHsp" style=""></span>cm), free surgical margins, negative SLNB, and the absence of poor prognostic factors, such as lymphovascular invasion and immunodeficiency.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a></p><p id="par0215" class="elsevierStylePara elsevierViewall">A retrospective analysis of 46 low-risk head and neck MCC cases treated between 2006 and 2015 demonstrated that failure to perform postoperative RT was associated with a significantly higher risk of local recurrence (five-year local recurrence of 26% in the group treated without adjuvant RT <span class="elsevierStyleItalic">versus</span> 0% in the group that received adjuvant RT, p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.02). Patients were considered low-risk if they had a primary tumor ≤ 2.0<span class="elsevierStyleHsp" style=""></span>cm in diameter, microscopically negative margins on surgical excision, negative SLNB, and no chronic immunosuppression.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a></p><p id="par0220" class="elsevierStylePara elsevierViewall">Jouary Y et al. showed a significant reduction in local recurrence with no improvement in overall survival with adjuvant RT in a study conducted before the introduction of SLNB in the treatment of MCC.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">40</span></a></p><p id="par0225" class="elsevierStylePara elsevierViewall">In a retrospective non-randomized cohort of 6908 cases from the US National Cancer Database, adjuvant RT was associated with improved survival in patients with localized MCC (stages I and II) compared with patients who underwent surgical treatment alone (stage I: Hazard Ratio [HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.71], 95% CI: 0.64‒0.80, p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001; stage II: HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.77, 95% CI: 0.66‒0.89, p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001). However, in patients with nodal involvement (stage III), there was no statistically significant difference in OS between patients who had surgery followed by RT compared to those submitted to surgery alone (HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.98, 95% CI: 0.86–1.12, p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.80).<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">41</span></a></p><p id="par0230" class="elsevierStylePara elsevierViewall">In contrast, a retrospective study from the Moffitt Cancer Center, evaluating 171 patients, found an improvement in locoregional control and OS in patients with pathologically or clinically positive lymph nodes treated with postoperative RT. In this publication, the patients were treated with wide local excision (1–2<span class="elsevierStyleHsp" style=""></span>cm margins) and all of them underwent nodal staging.<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">42</span></a></p><p id="par0235" class="elsevierStylePara elsevierViewall">Thus, the NCCN included RT as an adjunctive treatment option for all MCC stages and should ideally be performed within 4–6 weeks of surgery, as the delay has been associated with worse outcomes.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p></span></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Systemic treatment</span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Chemotherapy</span><p id="par0240" class="elsevierStylePara elsevierViewall">The role of adjuvant CT for MCC is less well defined. Hasan et al. performed a large systematic review and found that adjuvant RT resulted in significantly higher three-year local control rates, decreased recurrence rates, and improved three-year OS rates, whereas adjuvant CT provided no benefits.<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">43</span></a> Moreover, additional studies suggest that the effect of adjuvant chemotherapy on recurrence is unclear or that there is no significant survival improvement when compared to adjuvant RT alone.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">29,44,45</span></a></p><p id="par0245" class="elsevierStylePara elsevierViewall">For many years, CT was the only option available as treatment for advanced disease. MCC is considered a chemosensitive tumor and treatment regimens of platinum with etoposide or taxanes and anthracyclines alone or in combination are initially effective, with a response rate of up to 75%, but usually, the duration of response is short, not resulting in survival benefit. Median progression-free survival (PFS) ranges from three to eight months, and the duration of partial response is only three months for the first-line therapy.<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25,46</span></a> Given the advanced age of many patients and their comorbidities, CT toxicity can severely affect patients quality of life.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Immunotherapy</span><p id="par0250" class="elsevierStylePara elsevierViewall">Immunotherapies are currently the center of attention, since the importance of the immune system in MCC control has been described, with PD-1 (programmed cell death 1) and PD-L1 (programmed cell death protein ligand 1) inhibitors being promising options in cases of metastatic disease.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a></p><p id="par0255" class="elsevierStylePara elsevierViewall">The PD-1 and PD-L1/PD-L2 pathways constitute a complex system of receptors and ligands involved in controlling T-cell activation. In most tumors, PD-L1 is predominantly expressed in tumor cells and PD-1 in lymphocytes that infiltrate the tumor.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> However, PD-1 can be expressed not only by CD8+ T lymphocytes, but also by CD4+, CD20+, Treg, and NK cells.<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">47</span></a> The binding between PD-1 and its PD-L1 ligand leads to the inactivation and decreased proliferation of T cells. This process seems to be an important mechanism for the immune response inhibition by the tumor.<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">48</span></a></p><p id="par0260" class="elsevierStylePara elsevierViewall">The association of immunosuppression with increased risk of MCC, in addition to some data that show a better prognosis in tumors with high infiltration of CD8+ T lymphocytes, has become a justification for immunotherapy use.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,49</span></a> Additionally, Lipson et al., in 2013, reported a significant association between the presence of MCPyV and PD-L1 expression in the tumor and between the presence of MCPyV and a moderate to intense inflammatory infiltrate. These findings suggest that an immune response to viral antigens creates a local pro-inflammatory environment that stimulates PD-L1 expression in the tumor.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">50</span></a> These findings paved the way for the use of immune checkpoint inhibitors in metastatic MCC.</p><p id="par0265" class="elsevierStylePara elsevierViewall">The first study in this scenario was JAVELIN Merkel 200, an open, phase II multicenter clinical trial that investigated the clinical activity and safety of avelumab, an anti-PD-L1 antibody. The study features part A, performed in patients with MCC who were previously exposed to CT,<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">51</span></a> and part B, performed in patients who had not received prior systemic treatment for metastatic disease.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a> In part A, 88 patients were treated with avelumab and the confirmed overall response rate (ORR) was 33% (including ten complete responses) with 26% of patients without disease progression at two years. The median duration of the response was not reached and the median OS was 12.6 months.<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">51</span></a> An objective response of 34.5% was found in PD-L1 positive <span class="elsevierStyleItalic">versus</span> only 18.8% in PDL-1 negative patients (expression <1%). Considering the 5% cutoff in PD-L1 expression; 52.6% of PD-L1 positive patients <span class="elsevierStyleItalic">versus</span> 23.6% of PD-L1 negative patients had an objective response. Furthermore; 26.1% of patients with MCPyV-positive tumors compared to 35.5% with MCPyV-negative tumors had a response.<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a> Another subgroup analysis suggested a greater likelihood of response in patients who received fewer prior systemic therapies, which was confirmed in part B of the Javelin Merkel 200 trial. The objective response among the 29 patients included in the first-line scenario was 62%, with 83% of responses lasting six months or more.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a></p><p id="par0270" class="elsevierStylePara elsevierViewall">Munhoz et al., in 2020, described the experience with avelumab as a second-line treatment (or first-line in patients not candidates for chemotherapy) in a subset of 46 Latin American patients (mean age: 71.6 years; 60.9% male; mean duration of treatment: 7.9 months). Objective responses were observed in 19 patients (objective response: 57.9%; complete response: 15.8%; partial response: 42.1% and stable disease: 10.5%) and safety was consistent with global data.<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a></p><p id="par0275" class="elsevierStylePara elsevierViewall">Another study with similar characteristics demonstrated the effectiveness of pembrolizumab in MCC, an anti-PD-1 monoclonal antibody. A total of 50 patients with advanced MCC were treated with an objective response of 56% and a six-month PFS rate of 67%. In contrast to the avelumab study, a higher response rate was seen in MCPyV-positive tumors (62%) than in MCPyV-negative ones (44%).<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">55</span></a></p><p id="par0280" class="elsevierStylePara elsevierViewall">In the CheckMate 358 study, nivolumab, another anti-PD-1, was evaluated in 25 patients with advanced MCC, with an objective response of 64%. The responses occurred in treatment-naïve patients (71%) as well as those with at least one prior systemic therapy (63%), with a short median time to response (75% of patients responded within two months).<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">56</span></a></p><p id="par0285" class="elsevierStylePara elsevierViewall">The summary of recent studies with immunotherapy for the treatment of metastatic MCC is depicted in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>.<a class="elsevierStyleCrossRefs" href="#bib0260"><span class="elsevierStyleSup">52,56–58</span></a></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0290" class="elsevierStylePara elsevierViewall">Given the efficacy of immunotherapy for metastatic MCC, the next challenge is to evaluate such treatments in the adjuvant scenario. Due to the high risk of MCC recurrence, despite the initial treatment and lack of benefit from cytotoxic treatment, its investigation is highly relevant, covering an unmet medical need. Two-phase II trials with nivolumab and avelumab are evaluating the use of immune checkpoint inhibitors for high-risk patients yet without officially published results. The neoadjuvant scenario with the CheckMate 358 trial, involving 39 patients with stage IIA to IV resectable MCC, evaluated the use of nivolumab (≥1 dose) approximately four weeks before surgery. Three patients were not submitted to surgery due to tumor progression and 36 patients were submitted, of which 17 (42.2%) attained a complete pathological response. Among 33 radiographically evaluated patients who underwent surgery, 18 (54.5%) showed tumor reduction ≥30%. No patient with a pathological complete response had tumor recurrence during the observation period.<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">59</span></a></p></span></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Conclusion</span><p id="par0295" class="elsevierStylePara elsevierViewall">MCC is a rare and aggressive disease, whose incidence is increasing. In recent decades, many advances have been made regarding the knowledge related to the biology, diagnosis and treatment of MCC, but great challenges still remain. Primary tumors should be treated with complete surgical excision with adequate surgical margins. Adjuvant RT should be considered. Regarding advanced MCC, immunotherapy has drastically changed the standard of care, as it is superior to chemotherapy. Remarkable responses have been seen in MCC patients treated with PD-1/PD-L1 axis inhibitors and it seems to be a promising way to change the prognosis of this aggressive skin cancer.</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Financial support</span><p id="par0300" class="elsevierStylePara elsevierViewall">None declared.</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Authors' contributions</span><p id="par0305" class="elsevierStylePara elsevierViewall">Stella Meireles Siqueira: Statistical analysis; drafting and editing of the manuscript; collection, analysis, and interpretation of data; intellectual participation in propaedeutic and/or therapeutic conduct of studied cases; critical review of the literature.</p><p id="par0310" class="elsevierStylePara elsevierViewall">Gabriella Campos-do-Carmo: Statistical analysis; drafting and editing of the manuscript; collection, analysis, and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases.</p><p id="par0315" class="elsevierStylePara elsevierViewall">Alexssandra Lima Siqueira dos Santos: Statistical analysis; drafting and editing of the manuscript; collection, analysis, and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature.</p><p id="par0320" class="elsevierStylePara elsevierViewall">Cícero Martins: Statistical analysis; drafting and editing of the manuscript; collection, analysis, and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature.</p><p id="par0325" class="elsevierStylePara elsevierViewall">Andreia Cristina de Melo: Statistical analysis; approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; effective participation in research orientation; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the manuscript.</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conflicts of interest</span><p id="par0330" class="elsevierStylePara elsevierViewall">None declared.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:17 [ 0 => array:3 [ "identificador" => "xres1897579" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1641768" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 3 => array:2 [ "identificador" => "sec0010" "titulo" => "Epidemiology" ] 4 => array:2 [ "identificador" => "sec0015" "titulo" => "Risk factors" ] 5 => array:2 [ "identificador" => "sec0020" "titulo" => "Polyomavirus associated with Merkel cell carcinoma" ] 6 => array:2 [ "identificador" => "sec0025" "titulo" => "Clinical features" ] 7 => array:2 [ "identificador" => "sec0030" "titulo" => "Diagnosis" ] 8 => array:2 [ "identificador" => "sec0035" "titulo" => "Differential diagnosis" ] 9 => array:2 [ "identificador" => "sec0040" "titulo" => "Staging" ] 10 => array:3 [ "identificador" => "sec0045" "titulo" => "Treatment" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0050" "titulo" => "Surgery for the primary tumor" ] 1 => array:2 [ "identificador" => "sec0055" "titulo" => "Radiotherapy" ] ] ] 11 => array:3 [ "identificador" => "sec0060" "titulo" => "Systemic treatment" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0065" "titulo" => "Chemotherapy" ] 1 => array:2 [ "identificador" => "sec0070" "titulo" => "Immunotherapy" ] ] ] 12 => array:2 [ "identificador" => "sec0075" "titulo" => "Conclusion" ] 13 => array:2 [ "identificador" => "sec0080" "titulo" => "Financial support" ] 14 => array:2 [ "identificador" => "sec0085" "titulo" => "Authors' contributions" ] 15 => array:2 [ "identificador" => "sec0090" "titulo" => "Conflicts of interest" ] 16 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2022-07-28" "fechaAceptado" => "2022-09-16" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1641768" "palabras" => array:4 [ 0 => "Carcinoma, Merkel cell" 1 => "Immune checkpoint inhibitors" 2 => "Merkel cell polyomavirus" 3 => "Skin neoplasms" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Merkel cell carcinoma is a rare skin cancer with neuroendocrine differentiation. The risk factors include sun exposure, advanced age, immunosuppression (such as transplant recipients, patients with lymphoproliferative neoplasms, or patients with HIV), and Merkel cell polyomavirus infection. Clinically, Merkel cell carcinoma appears as a cutaneous or subcutaneous plaque or nodule, but this tumor diagnosis is rarely made clinically. Therefore, histopathology and immunohistochemistry are usually necessary. Primary tumors without evidence of metastases are treated with complete surgical excision and appropriate surgical margins. The presence of occult metastasis in a lymph node is frequent and a sentinel lymph node biopsy should be performed. Postoperative adjuvant radiotherapy increases local tumor control. Recently, agents that block the PD-1/PD-L1 pathway have shown objective and durable tumor regression in patients with advanced solid malignancies. The first anti-PD-L1 antibody used in patients with Merkel cell carcinoma was avelumab, but pembrolizumab and nivolumab have also shown efficacy. This article describes the current state of knowledge of the epidemiology, diagnosis, and staging of Merkel cell carcinoma, as well as new strategies for its systemic treatment.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Study conducted at the Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil.</p>" ] ] "multimedia" => array:5 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2528 "Ancho" => 1675 "Tamanyo" => 371116 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Immunohistochemistry for MCPyV performed on Merkel cell carcinoma slides. (A) Immunohistochemistry slide from a patient showing a positive result for MCPyV (×400 magnification). (B) Immunohistochemistry slide from a patient showing a negative result for MCPyV (×400 magnification).</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1889 "Ancho" => 2508 "Tamanyo" => 294872 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Merkel cell carcinoma located on the left thigh of a male patient. (A) At diagnosis, tumor lesion with cupuliform appearance, with erythema and mild desquamation. (B) Tumor evolution with growth and ulceration throughout the lesion. Source: Courtesy of Dr. Gabriella Campos-do-Carmo (the patient consented to the use of images for educational purposes).</p>" ] ] 2 => array:8 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 2590 "Ancho" => 1675 "Tamanyo" => 502785 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0015" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Histopathology of Merkel cell carcinoma with hematoxylin-eosin staining. (A) Cords of tumor cells in the dermis (×200 magnification). (B) Tumor cells showing scarce cytoplasm and round or irregular nuclei (×400 magnification).</p>" ] ] 3 => array:9 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Adapted source: Harms et al.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a>." "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0020" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Stage \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Primary Tumor \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Lymph nodes \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Metastases \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">In situ</span> (restricted to the epidermis) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No metastasis in regional lymph nodes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No distant metastasis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">I</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="middle">Maximum clinical tumor diameter ≤2<span class="elsevierStyleHsp" style=""></span>cm</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">cN0, no metastasis to regional lymph nodes on clinical or radiological evaluation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">No distant metastasis</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">pN0, no metastasis to regional lymph nodes detected in the histopathological evaluation \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">IIA</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="middle">Maximum clinical tumor diameter >2<span class="elsevierStyleHsp" style=""></span>cm</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">cN0, no metastasis to regional lymph nodes on clinical or radiological evaluation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">No distant metastasis</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">pN0, no metastasis to regional lymph nodes detected in histopathological evaluation \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">IIB</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="middle">Primary tumor invades fascia, muscle, cartilage, or bone</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">cN0, no metastasis to regional lymph nodes on clinical or radiological evaluation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">No distant metastasis</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">pN0, no metastasis to regional lymph nodes detected in histopathological evaluation \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">III (clinical) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tumor of any size, including invasive tumors and unknown primary tumor \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinically detected regional lymph node metastasis, in-transit metastasis<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> with or without lymph node metastasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No distant metastasis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">IIIA (pathological)</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="middle">Tumor of any size, including invasive tumors and unknown primary tumor</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinically occult lymph node metastasis identified only by SLNB or lymph node dissection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">No distant metastasis</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinically or radiologically detected regional lymph node metastasis, pathologically confirmed \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IIIB (pathological) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tumor of any size, including invasive tumors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinically or radiologically detected regional lymph node metastasis, pathologically confirmed, in-transit metastasis<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> with or without lymph node metastasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tumor of any size, including invasive tumors and unknown primary tumor \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Any N \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metastasis beyond regional lymph nodes \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3171474.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">In-transit metastasis: a tumor distinct from the primary lesion and located between the primary lesion and regional lymph nodes or distal to the primary lesion.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Staging of Merkel cell carcinoma – AJCC 8<span class="elsevierStyleSup">th</span> edition.</p>" ] ] 4 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0025" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">ORR, Overall response rate; PFS, Progression free survival; OS, Overall Survival; NR, Not reported.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Study name \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Drug class \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Type of study \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Number of patients \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">ORR (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">PFS at 24<span class="elsevierStyleHsp" style=""></span>m (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">OS at 24<span class="elsevierStyleHsp" style=""></span>m (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">References \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Avelumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Javelin 200 ‒ Part A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Anti-PD-L1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2<span class="elsevierStyleSup">nd</span> line or subsequent lines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">88 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">36 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Kaufman 2018<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">57</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Avelumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Javelin 200 ‒ Part B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Anti-PD-L1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1<span class="elsevierStyleSup">st</span> line \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">62 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">D’Angelo, 2018<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pembrolizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Keynote ‒ 017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Anti-PD-1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1<span class="elsevierStyleSup">st</span> line \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">48.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">68.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nghiem, 2019<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">58</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Nivolumab</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="middle">CheckMate 358</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">Anti-PD-1</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1<span class="elsevierStyleSup">st</span> line \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">71 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">NR</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">NR</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="middle">Topalian, 2017<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">56</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2<span class="elsevierStyleSup">nd</span> line \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">63 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3171475.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Important data from recent clinical trials involving immunotherapy<a class="elsevierStyleCrossRefs" href="#bib0260"><span class="elsevierStyleSup">52,56–58</span></a>.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:59 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "U. Wehkamp" 1 => "S. Stern" 2 => "S. Krüger" 3 => "M. Weichenthal" 4 => "A. Hauschild" 5 => "C. Röcken" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00432-018-2657-x" "Revista" => array:6 [ "tituloSerie" => "J Cancer Res Clin Oncol" "fecha" => "2018" "volumen" => "144" "paginaInicial" => "1301" "paginaFinal" => "1308" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29744662" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trabecular carcinoma of the skin" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "C. Toker" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Archives of Dermatology" "fecha" => "1972" "volumen" => "105" "paginaInicial" => "107" "paginaFinal" => "110" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/5009611" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The biology and treatment of Merkel cell carcinoma: current understanding and research priorities" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.W. Harms" 1 => "K.L. Harms" 2 => "P.S. Moore" 3 => "J.A. DeCaprio" 4 => "P. Nghiem" 5 => "M.K.K. Wong" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Nat Ver Clin Oncol" "fecha" => "2018" "volumen" => "15" "paginaInicial" => "763" "paginaFinal" => "766" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Van der Zwan" 1 => "A. Trama" 2 => "R. Otter" 3 => "N. Larrañaga" 4 => "A. Tavilla" 5 => "R. Marcos-Gragera" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejca.2013.02.029" "Revista" => array:6 [ "tituloSerie" => "Eur J Cancer" "fecha" => "2013" "volumen" => "49" "paginaInicial" => "2565" "paginaFinal" => "2578" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23541566" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dramatic Increase in the Incidence and Mortality from Merkel Cell Carcinoma in the United States" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.L. Fitzgerald" 1 => "S. Dennis" 2 => "S.D. Kachare" 3 => "N.A. Vohra" 4 => "J.H. Wong" 5 => "E.E. Zervos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/000313481508100819" "Revista" => array:6 [ "tituloSerie" => "The American Surgeon" "fecha" => "2015" "volumen" => "81" "paginaInicial" => "802" "paginaFinal" => "806" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26215243" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.G. Paulson" 1 => "S.Y. Park" 2 => "N.A. Vandeven" 3 => "K. Lachance" 4 => "H. Thomas" 5 => "A.G. Chapuis" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2018" "volumen" => "78" "paginaInicial" => "457" "paginaFinal" => "463" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993-2010" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D.R. Youlden" 1 => "H.P. Soyer" 2 => "P.H. Youl" 3 => "L. Fritschi" 4 => "P.D. Baade" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamadermatol.2014.124" "Revista" => array:6 [ "tituloSerie" => "JAMA Dermatol" "fecha" => "2014" "volumen" => "150" "paginaInicial" => "864" "paginaFinal" => "872" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24943712" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.K. Bichakjian" 1 => "T. Olencki" 2 => "S.Z. Aasi" 3 => "M. Alam" 4 => "J.S. Anderson" 5 => "R. Blitzblau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.6004/jnccn.2018.0055" "Revista" => array:6 [ "tituloSerie" => "J Natl Compr Canc Netw" "fecha" => "2018" "volumen" => "16" "paginaInicial" => "742" "paginaFinal" => "774" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29891526" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trends in the incidence and morbidity of Merkel cell carcinoma in Brazil" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.C. Melo" 1 => "L.S. Thuler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2217/fon-2020-1313" "Revista" => array:6 [ "tituloSerie" => "Future Oncology" "fecha" => "2020" "volumen" => "17" "paginaInicial" => "2857" "paginaFinal" => "2865" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33960199" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel cell carcinoma: clinical presentation, prognostic factors, treatment and survival in 32 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C. Carneiro" 1 => "J.C. Sbalchiero" 2 => "B.R. Caiado Neto" 3 => "G.B. Graziosi" 4 => "F.P. Dumaresq" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Bras Cir" "fecha" => "2013" "volumen" => "28" "paginaInicial" => "196" "paginaFinal" => "200" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clonal integration of a polyomavirus in human Merkel cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "H. Feng" 1 => "M. Shuda" 2 => "Y. Chang" 3 => "P.S. Moore" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1126/science.1152586" "Revista" => array:6 [ "tituloSerie" => "Science" "fecha" => "2008" "volumen" => "319" "paginaInicial" => "1096" "paginaFinal" => "1100" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18202256" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "H. Sihto" 1 => "H. Kukko" 2 => "V. Koljonen" 3 => "R. Sankila" 4 => "T. Böhling" 5 => "H. Joensuu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jnci/djp139" "Revista" => array:6 [ "tituloSerie" => "J Natl Cancer Inst" "fecha" => "2009" "volumen" => "101" "paginaInicial" => "938" "paginaFinal" => "945" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19535775" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel Cell Carcinoma ‒ Current Controversies and Future Directions" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "N. Steven" 1 => "P. Lawton" 2 => "M. Poulsen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clon.2019.08.012" "Revista" => array:6 [ "tituloSerie" => "Clinical Oncology" "fecha" => "2019" "volumen" => "31" "paginaInicial" => "789" "paginaFinal" => "796" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31594644" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NCCN Guidelines Index Table of Contents Discussion" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.D. Schmults" 1 => "R. Blitzblau" 2 => "S.Z. Aasi" 3 => "M. Alam" 4 => "J.S. Andersen" 5 => "J.S. Bordeaux" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Merkel Cell Carcinoma" "fecha" => "2019" "volumen" => "66" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Heath" 1 => "N. Jaimes" 2 => "B. Lemos" 3 => "A. Mostaghimi" 4 => "L.C. Wang" 5 => "P.F. Peñas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2007.11.020" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2008" "volumen" => "58" "paginaInicial" => "375" "paginaFinal" => "381" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18280333" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E.J. Lunder" 1 => "R.S. Stern" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199810223391715" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1998" "volumen" => "339" "paginaInicial" => "1247" "paginaFinal" => "1248" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9786759" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunohistochemistry for Merkel cell polyomavirus is highly specific but not sensitive for the diagnosis of Merkel cell carcinoma in the Australian population" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.Y. Paik" 1 => "G. Hall" 2 => "A. Clarkson" 3 => "L. Lee" 4 => "C. Toon" 5 => "A. Colebatch" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.humpath.2010.12.013" "Revista" => array:6 [ "tituloSerie" => "Hum Pathol" "fecha" => "2011" "volumen" => "42" "paginaInicial" => "1385" "paginaFinal" => "1390" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21453956" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Bhatia" 1 => "O. Afanasiev" 2 => "P. Nghiem" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Curr Oncol Rep" "fecha" => "2011" "volumen" => "13" "paginaInicial" => "488" "paginaFinal" => "497" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Schadendorf" 1 => "C. Lebbé" 2 => "A.Z. Hausen" 3 => "M.F. Avril" 4 => "S. Hariharan" 5 => "M. Bharmal" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur J Cancer" "fecha" => "2017" "volumen" => "71" "paginaInicial" => "53" "paginaFinal" => "69" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel cell carcinoma: An update and review: Pathogenesis, diagnosis, and staging" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K. Coggshall" 1 => "T.L. Lello" 2 => "J.P. North" 3 => "S.S. Yu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2017.12.001" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2018" "volumen" => "78" "paginaInicial" => "433" "paginaFinal" => "442" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29229574" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Samimi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40257-019-00427-9" "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2019" "volumen" => "20" "paginaInicial" => "391" "paginaFinal" => "407" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30784027" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S.G. Gupta" 1 => "L.C. Wang" 2 => "P.F. Peñas" 3 => "M. Gellenthin" 4 => "S.J. Lee" 5 => "P. Nghiem" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2006" "paginaInicial" => "142685" "paginaFinal" => "142690" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.B. Colgan" 1 => "T.I. Tarantola" 2 => "A.L. Weaver" 3 => "G.A. Wiseman" 4 => "R.K. Roenigk" 5 => "J.D. Brewer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2012.03.018" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2012" "volumen" => "67" "paginaInicial" => "1250" "paginaFinal" => "1256" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22552001" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.L. Harms" 1 => "M.A. Healy" 2 => "P. Nghiem" 3 => "A.J. Sober" 4 => "T.M. Johnson" 5 => "C.K. Bichakjian" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1245/s10434-016-5266-4" "Revista" => array:6 [ "tituloSerie" => "Ann Surg Oncol" "fecha" => "2016" "volumen" => "23" "paginaInicial" => "3564" "paginaFinal" => "3571" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27198511" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Updates on Merkel Cell Carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D.A. Emge" 1 => "A.R. Cardones" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.det.2019.06.002" "Revista" => array:6 [ "tituloSerie" => "Dermatol Clin" "fecha" => "2019" "volumen" => "37" "paginaInicial" => "489" "paginaFinal" => "503" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31466589" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Local control of primary Merkel cell carcinoma: review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.D. Boyer" 1 => "J.A. Zitelli" 2 => "D.G. Brodland" 3 => "G. D’Angelo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1067/mjd.2002.125083" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2002" "volumen" => "47" "paginaInicial" => "885" "paginaFinal" => "892" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12451374" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Demographics and outcomes of stage I and II Merkel cell carcinoma treated with Mohs micrographic surgery compared with wide local excision in the National Cancer Database" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "B. Singh" 1 => "M.M. Qureshi" 2 => "M.T. Truong" 3 => "D. Sahni" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2018.01.041" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2018" "volumen" => "79" "paginaInicial" => "126" "paginaFinal" => "134" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29408552" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel cell carcinoma: 30-year experience from a single institution" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.A. Santamaria-Barria" 1 => "G.M. Boland" 2 => "B.Y. Yeap" 3 => "V. Nardi" 4 => "D. Dias-Santagata" 5 => "J.C. Cusack Jr" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1245/s10434-012-2779-3" "Revista" => array:6 [ "tituloSerie" => "Ann Surg Oncol" "fecha" => "2013" "volumen" => "20" "paginaInicial" => "1365" "paginaFinal" => "1373" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23208132" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel cell carcinoma ‒ current therapeutic options" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Poulsen" 1 => "D. Rischin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Expert Opin Pharmacother" "fecha" => "2003" "volumen" => "4" "paginaInicial" => "12" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful local control of cutaneous Merkel cell carcinoma on the eyelid with CyberKnife radiosurgery" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Tuskada" 1 => "T. Fujimura" 2 => "A. Hashimoto" 3 => "Y. Kambayashi" 4 => "S. Furudate" 5 => "T. Haga" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1684/ejd.2013.2123" "Revista" => array:6 [ "tituloSerie" => "Eur J Dermatol" "fecha" => "2013" "volumen" => "23" "paginaInicial" => "725" "paginaFinal" => "726" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24063985" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Definitive radiotherapy for Merkel cell carcinoma confers clinically meaningful in-field locoregional control: A review and analysis of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.A. Gunaratne" 1 => "J.R. Howle" 2 => "M.J. Veness" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2017.02.015" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2017" "volumen" => "77" "paginaInicial" => "142" "paginaFinal" => "148" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28495499" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Strom" 1 => "A.O. Naghavi" 2 => "J.L. Messina" 3 => "S. Kim" 4 => "J.F. Torres-Roca" 5 => "J. Russell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hed.24527" "Revista" => array:6 [ "tituloSerie" => "Head Neck" "fecha" => "2017" "volumen" => "39" "paginaInicial" => "48" "paginaFinal" => "55" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27300153" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of radiotherapy alone in patients with merkel cell carcinoma: reporting the Australian experience of 43 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Veness" 1 => "M. Foote" 2 => "V. Gebski" 3 => "M. Poulsen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ijrobp.2009.08.011" "Revista" => array:6 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "2010" "volumen" => "78" "paginaInicial" => "703" "paginaFinal" => "709" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19939581" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P. Mojica" 1 => "D. Smith" 2 => "J.D.I. Ellenhorn" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2006.07.9319" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2007" "volumen" => "25" "paginaInicial" => "1043" "paginaFinal" => "1047" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17369567" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiotherapy alone in patients with Merkel cell carcinoma: the Westmead Hospital experience of 41 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Veness" 1 => "J. Howle" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ajd.12263" "Revista" => array:6 [ "tituloSerie" => "Australas J Dermatol" "fecha" => "2015" "volumen" => "56" "paginaInicial" => "19" "paginaFinal" => "24" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25369110" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of adjuvant therapy in the management of head and neck Merkel cell carcinoma: an analysis of 4815 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.M. Chen" 1 => "S.A. Roman" 2 => "J.A. Sosa" 3 => "B.L. Judson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "JAMA Otolaryngol Head Neck Surg" "fecha" => "2015" "volumen" => "141" "paginaInicial" => "137" "paginaFinal" => "141" ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.C. Fields" 1 => "K.J. Busam" 2 => "J.F. Chou" 3 => "K.S. Panageas" 4 => "M.P. Pulitzer" 5 => "P.J. Allen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cancer" "fecha" => "2012" "volumen" => "118" "paginaInicial" => "3311" "paginaFinal" => "3320" ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "N.J. Miller" 1 => "S. Bhatia" 2 => "U. Parvathaneni" 3 => "J.G. Iyer" 4 => "P. Nghiem" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11864-013-0225-9" "Revista" => array:6 [ "tituloSerie" => "Curr Treat Options Oncol" "fecha" => "2013" "volumen" => "14" "paginaInicial" => "249" "paginaFinal" => "263" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23436166" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Postoperative radiation therapy is associated with a reduced risk of local recurrence among low risk Merkel cell carcinomas of the head and neck" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.R. Takagishi" 1 => "T.E. Marx" 2 => "C. Lewis" 3 => "E.S. Tarabadkar" 4 => "I.D. Juhlin" 5 => "A. Blom" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.adro.2016.10.003" "Revista" => array:6 [ "tituloSerie" => "Adv Radiat Oncol" "fecha" => "2016" "volumen" => "1" "paginaInicial" => "244" "paginaFinal" => "251" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28740894" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Jouary" 1 => "C. Leyral" 2 => "B. Dreno" 3 => "A. Doussau" 4 => "B. Sassolas" 5 => "M. Beylot-Barry" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdr318" "Revista" => array:6 [ "tituloSerie" => "Annals of Oncology" "fecha" => "2012" "volumen" => "23" "paginaInicial" => "1074" "paginaFinal" => "1080" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21750118" "web" => "Medline" ] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Bhatia" 1 => "B.E. Storer" 2 => "J.G. Lyer" 3 => "A. Moshiri" 4 => "U. Parvathaneni" 5 => "D. Byrd" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "J Natl Cancer Inst" "fecha" => "2016" "volumen" => "108" ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Strom" 1 => "M. Carr" 2 => "S. Zager" 3 => "A. Naghavi" 4 => "F.O. Smith" 5 => "C.W. Cruse" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1245/s10434-016-5293-1" "Revista" => array:6 [ "tituloSerie" => "Ann Surg Oncol" "fecha" => "2016" "volumen" => "23" "paginaInicial" => "3572" "paginaFinal" => "3578" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27251134" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of postoperative radiation and chemoradiation in merkel cell carcinoma: a systematic review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Hasan" 1 => "L. Liu" 2 => "J. Triplet" 3 => "Z. Li" 4 => "D. Mansur" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Front Oncoly" "fecha" => "2013" "volumen" => "3" "paginaInicial" => "276" ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel cell carcinoma: prognosis and treatment of patients from a single institution" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P.J. Allen" 1 => "W.B. Bowne" 2 => "D.P. Jaques" 3 => "M.F. Brennan" 4 => "K. Busam" 5 => "D.G. Coit" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2005" "paginaInicial" => "232300" "paginaFinal" => "232309" ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of merkel cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "T.Y. Eng" 1 => "M.G.K. Boersma" 2 => "C.D. Fuller" 3 => "S.X. Cavanaugh" 4 => "F. Venezuela" 5 => "T.S. Herman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.coc.0000135567.62750.f4" "Revista" => array:6 [ "tituloSerie" => "Am J Clin Oncol" "fecha" => "2004" "volumen" => "27" "paginaInicial" => "510" "paginaFinal" => "515" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15596922" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0230" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.R. Satpute" 1 => "N.R. Ammakkanavar" 2 => "L.H. Einhorn" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2014" "volumen" => "32" "paginaInicial" => "15" ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0235" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N.A. Giraldo" 1 => "P. Nguyen" 2 => "E.L. Engle" 3 => "G.J. Kaunitz" 4 => "T.R. Cottrell" 5 => "S. Berry" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Immunother Cancer" "fecha" => "2018" "volumen" => "6" "paginaInicial" => "99" ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0240" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.P. Patel" 1 => "R. Kurzrock" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/1535-7163.MCT-14-0983" "Revista" => array:6 [ "tituloSerie" => "Mol Cancer Ther" "fecha" => "2015" "volumen" => "14" "paginaInicial" => "847" "paginaFinal" => "856" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25695955" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0245" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.G. Paulson" 1 => "J.G. Lyer" 2 => "A.R. Tegeder" 3 => "R. Thibodeau" 4 => "J. Schelter" 5 => "S. Koba" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2010.30.6308" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2011" "volumen" => "29" "paginaInicial" => "1539" "paginaFinal" => "1546" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21422430" "web" => "Medline" ] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0250" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.J. Lipson" 1 => "J.G. Vincent" 2 => "M. Loyo" 3 => "L.T. Kagohara" 4 => "B.S. Luber" 5 => "H. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/2326-6066.CIR-13-0034" "Revista" => array:6 [ "tituloSerie" => "Cancer Immunol Res" "fecha" => "2013" "volumen" => "1" "paginaInicial" => "54" "paginaFinal" => "63" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24416729" "web" => "Medline" ] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0255" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Nghiem" 1 => "S. Bhatia" 2 => "A.S. Brohl" 3 => "O. Hamid" 4 => "J.M. Mehnert" 5 => "P. Terheyden" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2018" "volumen" => "36" "paginaInicial" => "9507" ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0260" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.P. D’angelo" 1 => "J. Russell" 2 => "C. Lebbe" 3 => "B. Chmielowski" 4 => "T. Gambichler" 5 => "J.J. Grob" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "JAMA Oncol" "fecha" => "2018" "volumen" => "4" ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0265" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Shapiro" 1 => "H.J. Grote" 2 => "V. D’Urso" 3 => "A. Heydebreck" 4 => "L. Mahnke" 5 => "H. Kaufman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2017" "volumen" => "35" "paginaInicial" => "9557" ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0270" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts’ recommendations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.R. Munhoz" 1 => "F. Cayol" 2 => "L. Corrales" 3 => "R. Gerson" 4 => "M. Tilli" 5 => "E.O. Barreto" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00262-020-02756-9" "Revista" => array:6 [ "tituloSerie" => "Cancer Immunol Immunother" "fecha" => "2021" "volumen" => "70" "paginaInicial" => "1031" "paginaFinal" => "1036" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33104838" "web" => "Medline" ] ] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0275" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.T. Nghiem" 1 => "S. Bhatia" 2 => "E.J. Lipson" 3 => "R.R. Kudchadkar" 4 => "N.J. Miller" 5 => "L. Annamalai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1603702" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2016" "volumen" => "374" "paginaInicial" => "2542" "paginaFinal" => "2552" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27093365" "web" => "Medline" ] ] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0280" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.L. Topalian" 1 => "S. Bhatia" 2 => "A. Hollebecque" 3 => "A. Awada" 4 => "J.P. De Boer" 5 => "R.R. Kudchadkar" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Cancer Res" "fecha" => "2017" "volumen" => "77" "paginaInicial" => "CT074" ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0285" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.L. Kaufman" 1 => "J.S. Russell" 2 => "O. Hamid" 3 => "S. Bhatia" 4 => "P. Terheyden" 5 => "S.P. D’Angelo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s40425-017-0310-x" "Revista" => array:5 [ "tituloSerie" => "J Immunother Cancer" "fecha" => "2018" "volumen" => "6" "paginaInicial" => "7" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29347993" "web" => "Medline" ] ] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0290" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.T. Nghiem" 1 => "S. Bhatia" 2 => "E.J. Lipson" 3 => "W.H. Sharfman" 4 => "R.R. Kudchadkar" 5 => "A.S. Brohl" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2019" "volumen" => "37" "paginaInicial" => "693" "paginaFinal" => "702" ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0295" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.L. Gbgtb Topalian" 1 => "S. Bhatia" 2 => "A. Amin" 3 => "R.R. Kudchadkar" 4 => "W.H. Sharfman" 5 => "C. Lebbé" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.20.00201" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2020" "volumen" => "38" "paginaInicial" => "2476" "paginaFinal" => "2487" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32324435" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/03650596/0000009800000003/v3_202305121633/S0365059623000211/v3_202305121633/en/main.assets" "Apartado" => array:4 [ "identificador" => "80634" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Continuing Medical Education" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/03650596/0000009800000003/v3_202305121633/S0365059623000211/v3_202305121633/en/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059623000211?idApp=UINPBA00008Z" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 23 | 7 | 30 |
2024 October | 132 | 115 | 247 |
2024 September | 210 | 126 | 336 |
2024 August | 173 | 151 | 324 |
2024 July | 175 | 121 | 296 |
2024 June | 144 | 74 | 218 |
2024 May | 104 | 68 | 172 |
2024 April | 159 | 107 | 266 |
2024 March | 131 | 79 | 210 |
2024 February | 101 | 99 | 200 |
2024 January | 95 | 75 | 170 |
2023 December | 142 | 71 | 213 |
2023 November | 136 | 86 | 222 |
2023 October | 124 | 91 | 215 |
2023 September | 138 | 85 | 223 |
2023 August | 129 | 34 | 163 |
2023 July | 140 | 63 | 203 |
2023 June | 293 | 66 | 359 |
2023 May | 595 | 105 | 700 |
2023 April | 122 | 28 | 150 |
2023 March | 50 | 58 | 108 |